Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Continuous cell substrate considerations.

A S Lubiniecki1

  • 1SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania.

Bioprocess Technology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Viral validation strategy for recombinant products derived from established animal cell lines.

Cytotechnology·2012
Same author

Historical reflections on cell culture engineering.

Cytotechnology·2008
Same author

Validation of fermentation processes.

Developments in biologicals·2003
Same author

Recent trends in cell substrate considerations for continuous cell lines.

Current opinion in biotechnology·2001
Same author

Elimination of serum from cell culture medium.

Developments in biological standardization·1999
Same author

Relationships among product characterization, process validation and preclinical/clinical studies for well-characterized products.

Developments in biological standardization·1999
Same journal

Design, formulation, and optimization of media.

Bioprocess technology·1995
Same journal

Sterilization and containment.

Bioprocess technology·1995
Same journal

Immobilized animal cell bioreactors.

Bioprocess technology·1995
Same journal

Immobilized microorganism bioreactors.

Bioprocess technology·1995
Same journal

Stirred tank bioreactors.

Bioprocess technology·1995
Same journal

Fundamentals of bioreactor design.

Bioprocess technology·1995
See all related articles

Continuous cell lines (CCLs) are used to produce biologicals, but concerns about tumorigenicity risks persist. Current scientific tools and process validation ensure product safety, with extensive clinical data showing no evidence of increased cancer risk in patients receiving these products.

Area of Science:

  • Biotechnology and Biopharmaceutical Production
  • Risk Assessment in Biological Manufacturing
  • Molecular Biology and Virology

Background:

  • The use of continuous cell lines (CCLs) for biological product manufacturing has been debated for over 30 years due to potential tumorigenicity risks.
  • Manufacturers and regulatory bodies are actively developing science-based guidelines to mitigate these concerns.
  • Existing scientific tools and process validation strategies aim to ensure the safety of biologics produced in CCLs.

Purpose of the Study:

  • To review the scientific tools available for evaluating the risk of tumorigenicity from potential viral DNA and protein contaminants in biologicals produced using CCLs.
  • To assess the theoretical and experimental basis for tumorigenicity risks associated with CCL-derived products.
  • To discuss the role of process validation in assuring the safety of biologics manufactured in CCLs.

Related Experiment Videos

Main Methods:

  • Review of scientific literature and available tools for detecting viral DNA and protein contaminants.
  • Analysis of theoretical and experimental data regarding the tumorigenicity of residual cellular proteins and viral contaminants.
  • Examination of clinical trial data and post-market surveillance of patients receiving CCL-derived biologicals.
  • Evaluation of animal studies using vaccines produced in tumorigenic CCLs.

Main Results:

  • No theoretical or experimental evidence suggests that residual cellular proteins pose a significant tumorigenicity risk.
  • Scientific tools are adequate for characterizing risks from viruses and DNA, but product safety assurance requires process validation.
  • Extensive clinical experience with various biologics (e.g., tPA, erythropoietin, monoclonal antibodies) and vaccines (e.g., polio, rabies) produced in CCLs shows no evidence of tumorigenicity.
  • Animal studies with vaccines from highly tumorigenic CCLs (BHK-21) demonstrated no adverse oncogenic effects.

Conclusions:

  • Scientific characterization tools and process validation principles effectively address theoretical tumorigenicity risks associated with CCL-derived products.
  • Extensive human and animal data support the safety of biologicals produced using CCL substrates.
  • Current guidelines and practices allow for the safe production of recombinant biologicals and monoclonal antibodies in CCLs, posing no unreasonable risks.